You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 23, 2024

Investigational Drug Information for HDM201


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for HDM201?

HDM201 is an investigational drug.

There have been 16 clinical trials for HDM201. The most recent clinical trial was a Phase 1 trial, which was initiated on January 28th 2020.

The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, Myeloid, and Leukemia. The leading clinical trial sponsors are Novartis Pharmaceuticals, Centre Leon Berard, and Novartis.

There are eighteen US patents protecting this investigational drug and three hundred and forty-six international patents.

Recent Clinical Trials for HDM201
TitleSponsorPhase
A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell TransplantNovartis PharmaceuticalsPhase 1/Phase 2
Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic ImpairmentNovartis PharmaceuticalsPhase 1
A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.Novartis PharmaceuticalsPhase 1/Phase 2

See all HDM201 clinical trials

Clinical Trial Summary for HDM201

Top disease conditions for HDM201
Top clinical trial sponsors for HDM201

See all HDM201 clinical trials

US Patents for HDM201

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
HDM201 ⤷  Sign Up Formylated N-heterocyclic derivatives as FGFR4 inhibitors NOVARTIS AG (Basel, CH) ⤷  Sign Up
HDM201 ⤷  Sign Up Pharmaceutical combinations Novartis AG (Basel, CH) ⤷  Sign Up
HDM201 ⤷  Sign Up Anti-CDH6 antibody drug conjugates Novartis AG (Basel, CH) ⤷  Sign Up
HDM201 ⤷  Sign Up Modified cyclic dinucleotide compounds Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) ⤷  Sign Up
HDM201 ⤷  Sign Up Compositions and methods for activating "stimulator of interferon gene"--dependent signalling ADURO BIOTECH, INC. (Berkeley, CA) ⤷  Sign Up
HDM201 ⤷  Sign Up Antibody molecules to TIM-3 and uses thereof Novartis AG (Basel, CH) DANA-FARBER CANCER INSTITUTE, INC. (Boston, MA) Children's Medical Center Corporation (Boston, MA) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for HDM201

Drugname Country Document Number Estimated Expiration Related US Patent
HDM201 Australia AU2016238436 2035-03-25 ⤷  Sign Up
HDM201 Brazil BR112017016817 2035-03-25 ⤷  Sign Up
HDM201 Canada CA2976766 2035-03-25 ⤷  Sign Up
HDM201 China CN107667092 2035-03-25 ⤷  Sign Up
HDM201 European Patent Office EP3274344 2035-03-25 ⤷  Sign Up
HDM201 Japan JP2018509442 2035-03-25 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.